Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | U-2932 is a human diffuse large B-cell lymphoma (DLBCL) cell line established in 1996, derived from the ascites of a 29-year-old female patient. Clinically, the patient had been diagnosed with advanced Hodgkin lymphoma 16 years prior and subsequently developed secondary DLBCL following multiple cycles of chemotherapy and radiotherapy. At the molecular level, U-2932 belongs to the Activated B-cell-like (ABC) subtype of DLBCL. It serves as a critical research resource because it naturally recapitulates intratumoral clonal heterogeneity, comprising two stable and genetically distinct sister subclones (designated R1 and R2). Both subclones harbor a foundational amplification of the BCL2 gene; however, they diverged through secondary genetic rearrangements, resulting in the overexpression of BCL6 in the R1 subclone and the overexpression of MYC in the R2 subclone. Consequently, it is regarded as a premier model for investigating clonal evolution and validating targeted therapeutic pathways for aggressive B-cell malignancies. |
| Tissue | Lymphoid; Ascites |
| Disease | Diffuse Large B-Cell Lymphoma (DLBCL; ABC Subtype) |
| Morphology | Lymphoblast-like; small round cells growing singly and in tight clusters |
| Gender | Female |
| Age | 29 years |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Directly analyze tumor clonal architecture, subpopulation dynamics, and evolutionary drift. 2. Investigate signaling divergence mediated by concurrent BCL2/BCL6/MYC networks. 3. Dissect downstream signaling pathways of constitutive NF-κB activation in ABC-DLBCL. 4. Screen for targeted compounds, including BTK and BCL2 inhibitors, or epigenetic modulators. 5. Evaluate adaptive changes in target variants and surface immunophenotypes during serial passaging. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes, displays robust engraftment potential in immunocompromised mice |
| Karyotype | Human polyclonal hypodiploid karyotype; 45(43-46)<2n>, XX; exhibits roughly 20% polyploidy and complex structural rearrangements. |
| Genetic Profile | 1. Biclonality: Two distinct subpopulations are present, exhibiting significant differences in the expression profiles of cell surface markers CD19, CD20, and CD38. 2. Oncogene Expression: BCL2 demonstrates uniform overexpression; specifically, subclone 1 drives the aberrant expression of BCL6, while subclone 2 drives the aberrant expression of MYC. 3. Mutation: A mutation is present in the TP53 gene. 4. EBV Status: EBV-negative. |
| Immunophenotype | Positive for CD10, CD19, CD20, CD37, CD38, CD80, CD138, cyCD79a, cIgM, and HLA-DR; Negative for CD3 and CD13 |
| Growth Kinetics | Doubling time is approximately 48 to 50 hours |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Transfer the suspension, containing both single suspended cells and grape-like aggregates, into a conical tube. 2. Centrifuge at approximately 1000 rpm for 5 minutes. 3. Carefully aspirate the supernatant, taking care not to disturb the pelleted cells. 4. Add fresh, pre-warmed complete medium and gently resuspend the cells. (Note: Do not vigorously pipette to forcibly break apart naturally formed cell aggregates, as maintaining this aggregated state helps preserve cell viability.) 5. Transfer the cells into a new culture vessel. The seeding density should be no lower than 0.5 X 10^6 cells/mL. Safely maintain the working density between 1.0 X 10^6 and 1.5 X 10^6 cells/mL. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | Split optimal suspension cultures at a ratio of 1:2 to 1:3 |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 70% to 80% RPMI 1640 + 10% to 20% FBS + 10% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO01228 | Cas9 Stable Cell Line - U-2932 | Inquiry |
| CSC-RR00720 | Luciferase Reporter Cell Line - U-2932 | Inquiry |
| CSC-RR00856 | GFP Reporter Cell Line - U-2932 | Inquiry |
| CSC-RO01664 | OVAL Stable Cell Line - U-2932 | Inquiry |
| CSC-RO01917 | GFP/OVAL Stable Cell Line - U-2932 | Inquiry |
| CSC-RO02170 | Luc/OVAL Stable Cell Line - U-2932 | Inquiry |
| CSC-RO02423 | GFP/Luc/OVAL Stable Cell Line - U-2932 | Inquiry |
| CSC-RR01242 | Nluc Reporter Cell Line - U2932 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.